🇺🇸 FDA
Patent

US 10420748

Methods of treatment associated with the granulocyte colony-stimulating factor receptor

granted A61KA61K31/40A61K31/4015

Quick answer

US patent 10420748 (Methods of treatment associated with the granulocyte colony-stimulating factor receptor) held by Ligand Pharmaceuticals Incorporated expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/40, A61K31/4015, A61K31/4045, A61K31/41